Operator
Thanks for standing by, and welcome to UroGen Pharma’s Third Quarter 2026 Earnings Convention Name. [Operator Instructions]
I’d now like handy the decision over to Vincent Perrone, Senior Director of Investor Relations. Please go forward.
Vincent Perrone
Senior Director of Investor Relations
Thanks. Good morning, everybody, and welcome to UroGen Pharma’s Third Quarter 2026 Monetary Outcomes and Enterprise Replace Convention Name.
Earlier this morning, we issued a press launch offering an summary of our current company highlights and monetary outcomes for the quarter ended September 30, 2026. The discharge may be accessed on the Buyers portion of our web site at traders.urogen.com.
Becoming a member of me in the present day are Liz Barrett, President and Chief Government Officer; Dr. Mark Schoenberg, Chief Medical Officer; and Chris Degnan, Chief Monetary Officer.
On in the present day’s name, we will likely be guaranteeing forward-looking statements. These might embrace statements relating to our ongoing commercialization actions associated to ZUSDURI and JELMYTO, our ongoing and deliberate medical trials and nonclinical research industrial and medical growth milestones, market and income alternatives, our commercialization technique and expectations in addition to anticipated information, regulatory filings and choices, the significance of ZUSDURI’s development for UroGen’s long-term technique, anticipated advantages of our strategic collaboration with IntraGel Therapeutics, the potential advantages of our merchandise and product candidates, future R&D efforts and milestones, our
